NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, filing
Related Tickers: NRXP
TL;DR
NRXP filed an 8-K on 9/26 for events on 9/24, mostly financial docs.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting on events that occurred on September 24, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates NRX Pharmaceuticals is providing updated financial information and exhibits to the SEC, which is standard procedure for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any significant new risks or material adverse events.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former company name
- September 24, 2025 (date) — Earliest event date
- September 26, 2025 (date) — Filing date
FAQ
What is the primary purpose of this 8-K filing for NRX Pharmaceuticals?
The primary purpose of this 8-K filing is to report on 'Other Events' and to provide 'Financial Statements and Exhibits' as of September 24, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed on September 26, 2025.
What was the earliest event date reported in this filing?
The earliest event date reported in this filing was September 24, 2025.
What was NRX Pharmaceuticals' former company name?
NRX Pharmaceuticals, Inc.'s former company name was Big Rock Partners Acquisition Corp.
In which state is NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-09-26 08:01:09
Key Financial Figures
- $0.001 — registered Common Stock , par value $0.001 pershare NRXP The Nasdaq Stock Marke
Filing Documents
- nrxp20250926_8k.htm (8-K) — 32KB
- ex_864593.htm (EX-99.1) — 11KB
- nrxlogo.jpg (GRAPHIC) — 2KB
- 0001437749-25-029907.txt ( ) — 197KB
- nrxp-20250924.xsd (EX-101.SCH) — 4KB
- nrxp-20250924_def.xml (EX-101.DEF) — 13KB
- nrxp-20250924_lab.xml (EX-101.LAB) — 18KB
- nrxp-20250924_pre.xml (EX-101.PRE) — 14KB
- nrxp20250926_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 24, 2025, NRx Pharmaceuticals, Inc. (the "Company") issued a press release, in which the Company announced that it was notified by the United States Food and Drug Administration that a Suitability Petition has been granted for the strength proposed by the Company for its planned single-patient, preservative-free ketamine product (KETAFREE). Currently, ketamine is sold in multi-dose vials that contain Benzethonium Chloride, a toxic preservative. The Suitability Petition that has been granted enables immediate re-filing of the Company's Abbreviated New Drug Application for KETAFREE. A copy of the Press Release is furnished hereto as Exhibit 99.1 The information in this Item 8.01 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 8.01 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 24, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: September 26, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer